Gene: Apob (apolipoprotein B)  Mus musculus Symbol: Apob Name: apolipoprotein B Description: This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100. Unlike the apoB-48 and apoB-100 structural equivalents in human, which are synthesized exclusively in the gut and liver, respectively, the mouse apoB-48 isoform is also found in mouse liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2179 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. [provided by RefSeq, Jul 2008] Type: protein-coding RefSeq Status: REVIEWED Also known as: AI315052; Apo B-100; apob-100; apob-48; apolipoprotein B; apolipoprotein B-100; MGC176318; OTTMUSP00000049845; OTTMUSP00000049846 Orthologs: Homo sapiens : APOB (apolipoprotein B (including Ag(x) antigen))  HGNC Rattus norvegicus : Apob (apolipoprotein B) Latest Assembly: Mouse Genome Assembly Build 37 Position: Map Chr Position Strand Source Mouse Genome Assembly GRCm38 12 7,977,677 - 8,016,839 + NCBI Mouse cM Map 12 3.53   NCBI Mouse Celera Assembly 12 8,374,429 - 8,411,685 + NCBI Mouse Genome Assembly Build 37 12 7,984,483 - 8,023,645 + NCBI Mouse Genome Assembly Build 36.1 12 8,017,208 - 8,023,641 + NCBI Mouse Cytogenetic Map 12 A1.1   NCBI Model Launch Genome Browser (GBrowse) Annotation    (Toggle Detail/Summary View) Disease Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) Aortic Valve Stenosis   ISS   1578425   RGD   Arteriosclerosis   ISS RGD:735787 2312763 associated with Obesity RGD   Bile Duct Neoplasms   ISS RGD:735787 2325763 protein:increased expression:serum RGD   Bile Duct Neoplasms Susceptibility ISS RGD:735787 2317550 DNA:polymorphisms:intron, exon:IVS6+360C>T, 56C>T (human) RGD   Cerebral Infarction   ISS RGD:735787 2313973 protein:increased expression:serum RGD   Common Bile Duct Neoplasms   ISS RGD:735787 2325763 protein:increased expression:serum RGD   Coronary Artery Disease No_Association ISS   1578417   RGD   Coronary Artery Disease   ISS   1578418   RGD   Death   ISS RGD:735787 2313977 associated with Diabetes Mellitus, Insulin-Dependent RGD   Death, Sudden, Cardiac   ISS RGD:735787 1601197   RGD   Diabetes Mellitus   ISS RGD:735787 2313973 protein:increased expression:serum RGD   Diabetes Mellitus, Experimental   ISS RGD:2129 1642185   RGD   Diabetes Mellitus, Type 1   ISS RGD:735787 2313980   RGD   Diabetes Mellitus, Type 1   ISS RGD:735787 2313972   RGD   Diabetes Mellitus, Type 2   ISS RGD:735787 2313981   RGD   Diabetic Nephropathies   ISS RGD:735787 2313979 associated with Diabetes Mellitus, Non-Insulin-Dependent RGD   Diabetic Retinopathy   ISS RGD:735787 2313976 associated with Diabetes Mellitus, Non-Insulin-Dependent RGD   Endotoxemia   ISS RGD:2129 1599165   RGD   Fatty Liver   ISS RGD:2129 2325770 mRNA:increased expression:liver RGD   Gallbladder Neoplasms   ISS RGD:735787 2325761 DNA:SNP: :rs693 (human) RGD   Gallbladder Neoplasms Susceptibility ISS RGD:735787 2325764   RGD   Hypercholesterolemia   ISS RGD:2129 1599167   RGD   Hypercholesterolemia   ISS RGD:735787 7240710   OMIM   HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B   ISS RGD:735787 7240710   OMIM   Hyperlipidemia, Familial Combined   ISS RGD:735787 1601200 protein:increased expression:plasma RGD   Hyperlipidemias   ISS   1578419   RGD   Hyperlipoproteinemia Type II   ISS   1578415   RGD   Hyperlipoproteinemia Type II   ISS RGD:735787 7240710   OMIM   Hyperlipoproteinemia Type II   ISS RGD:735787 1626106   RGD   Hyperlipoproteinemia Type II   ISS RGD:735787 1580998   RGD   Hypobetalipoproteinemias Susceptibility ISS   1599164   RGD   Hypobetalipoproteinemias   ISS RGD:735787 7240710   OMIM   Hypobetalipoproteinemias   ISS RGD:735787 1601203 protein:decreased expression:plasma RGD   Metabolic Syndrome X   ISS RGD:735787 1601198 protein:increased expression:plasma RGD   Myocardial Ischemia   ISS   1578415   RGD   Obesity   IEP   2313974 associated with Insulin Resistance;protein:increased expression:plasma RGD   Gene-Chemical Interaction Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) (+)-alpha-tocopherol multiple interactions ISO RGD:735787 6480464 alpha-Tocopherol promotes the reaction [APOB protein results in increased reduction of Copper] CTD PMID:11368321 (+)-taxifolin decreases secretion ISO RGD:735787 6480464 taxifolin results in decreased secretion of APOB protein CTD PMID:15380446 (+)-taxifolin decreases expression ISO RGD:735787 6480464 taxifolin results in decreased expression of APOB protein CTD PMID:11108730 (-)-ephedrine multiple interactions ISO RGD:735787 6480464 [Ephedrine co-treated with Caffeine] results in decreased expression of APOB protein CTD PMID:16324916 (3S,5R)-fluvastatin multiple interactions ISO RGD:735787 6480464 [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin CTD PMID:19773416 (3S,5R)-fluvastatin multiple interactions ISO RGD:735787 6480464 fluvastatin promotes the reaction [[valsartan co-treated with benazepril] results in decreased expression of APOB protein] CTD PMID:20671225 17alpha-ethynylestradiol multiple interactions ISO RGD:735787 6480464 [Ethinyl Estradiol co-treated with Levonorgestrel] results in increased expression of APOB protein CTD PMID:15769986 17alpha-ethynylestradiol multiple interactions EXP   6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of APOB mRNA CTD PMID:17942748 17beta-estradiol increases stability ISO RGD:735787 6480464 Estradiol results in increased stability of APOB protein CTD PMID:11076531 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:2129 6480464 Tetrachlorodibenzodioxin results in increased expression of APOB mRNA CTD PMID:15644576 PMID:11752688 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP   6480464 Tetrachlorodibenzodioxin results in increased expression of APOB mRNA CTD PMID:22539624 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:2129 6480464 Tetrachlorodibenzodioxin results in decreased expression of APOB mRNA CTD PMID:20959002 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP   6480464 Tetrachlorodibenzodioxin results in decreased expression of APOB mRNA CTD PMID:21846477 2,3,7,8-tetrachlorodibenzodioxine multiple interactions EXP   6480464 Tetrachlorodibenzodioxin promotes the reaction [NFE2L2 gene mutant form results in decreased expression of APOB mRNA] CTD PMID:21846477 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:2129 6480464 Tetrachlorodibenzodioxin results in increased expression of APOB mRNA CTD PMID:11752688 PMID:15644576 2,3,7,8-tetrachlorodibenzodioxine multiple interactions EXP   6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of APOB mRNA CTD PMID:17942748 2,4,6-trinitrobenzenesulfonic acid decreases expression EXP   6480464 Trinitrobenzenesulfonic Acid results in decreased expression of APOB mRNA CTD PMID:17982090 2,4-dinitrotoluene affects expression ISO RGD:2129 6480464 2,4-dinitrotoluene affects the expression of APOB mRNA CTD PMID:21346803 2,6-dinitrotoluene affects expression ISO RGD:2129 6480464 2,6-dinitrotoluene affects the expression of APOB mRNA CTD PMID:21346803 2-amino-2-deoxy-D-glucopyranose increases degradation ISO RGD:2129 6480464 Glucosamine results in increased degradation of APOB protein CTD PMID:15618547 2-amino-2-deoxy-D-glucopyranose multiple interactions ISO RGD:735787 6480464 Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] CTD PMID:15618547 2-amino-2-deoxy-D-glucopyranose increases ubiquitination ISO RGD:735787 6480464 Glucosamine results in increased ubiquitination of APOB protein CTD PMID:15618547 2-amino-2-deoxy-D-glucopyranose decreases secretion ISO RGD:735787 6480464 Glucosamine results in decreased secretion of APOB protein CTD PMID:15618547 2-amino-2-deoxy-D-glucopyranose decreases localization ISO RGD:735787 6480464 Glucosamine results in decreased localization of APOB protein CTD PMID:15618547 2-amino-2-deoxy-D-glucopyranose decreases expression ISO RGD:735787 6480464 Glucosamine results in decreased expression of APOB protein CTD PMID:15618547 2-amino-2-deoxy-D-glucopyranose multiple interactions ISO RGD:735787 6480464 acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein] CTD PMID:19383982 2-amino-2-deoxy-D-glucopyranose multiple interactions ISO RGD:2129 6480464 Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] CTD PMID:15618547 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine increases expression ISO RGD:2129 6480464 Puromycin Aminonucleoside results in increased expression of APOB protein CTD PMID:7442475 more ... 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine increases expression ISO RGD:2129 6480464 Puromycin Aminonucleoside results in increased expression of APOB protein CTD PMID:2725289 more ... 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine increases expression ISO RGD:2129 6480464 Puromycin Aminonucleoside results in increased expression of APOB protein CTD PMID:8506949 more ... acetic anhydride multiple interactions ISO RGD:735787 6480464 [Sodium Acetate co-treated with acetic anhydride] results in increased acetylation of APOB protein CTD PMID:11304478 acetylleucyl-leucyl-norleucinal multiple interactions ISO RGD:735787 6480464 acetylleucyl-leucyl-norleucinal inhibits the reaction [4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline results in decreased secretion of APOB protein] CTD PMID:19342510 acetylleucyl-leucyl-norleucinal multiple interactions ISO RGD:735787 6480464 acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; more ... CTD PMID:19383982 aflatoxin B1 affects expression ISO RGD:735787 6480464 Aflatoxin B1 affects the expression of APOB protein CTD PMID:20106945 aldehydo-D-glucosamine multiple interactions ISO RGD:2129 6480464 Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] CTD PMID:15618547 aldehydo-D-glucosamine increases degradation ISO RGD:2129 6480464 Glucosamine results in increased degradation of APOB protein CTD PMID:15618547 aldehydo-D-glucosamine multiple interactions ISO RGD:735787 6480464 Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] CTD PMID:15618547 aldehydo-D-glucosamine increases ubiquitination ISO RGD:735787 6480464 Glucosamine results in increased ubiquitination of APOB protein CTD PMID:15618547 aldehydo-D-glucosamine decreases secretion ISO RGD:735787 6480464 Glucosamine results in decreased secretion of APOB protein CTD PMID:15618547 aldehydo-D-glucosamine decreases localization ISO RGD:735787 6480464 Glucosamine results in decreased localization of APOB protein CTD PMID:15618547 aldehydo-D-glucosamine decreases expression ISO RGD:735787 6480464 Glucosamine results in decreased expression of APOB protein CTD PMID:15618547 aldehydo-D-glucosamine multiple interactions ISO RGD:735787 6480464 acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein] CTD PMID:19383982 aluminium atom increases expression ISO RGD:735787 6480464 Aluminum results in increased expression of APOB protein CTD PMID:17762189 aluminium(0) increases expression ISO RGD:735787 6480464 Aluminum results in increased expression of APOB protein CTD PMID:17762189 ammonium chloride affects expression ISO RGD:2129 6480464 Ammonium Chloride affects the expression of APOB mRNA CTD PMID:16483693 Aroclor 1254 increases expression ISO RGD:2129 6480464 Chlorodiphenyl (54% Chlorine) results in increased expression of APOB mRNA CTD PMID:18178546 atenolol increases expression ISO RGD:735787 6480464 Atenolol results in increased expression of APOB CTD PMID:1928808 atenolol increases expression ISO RGD:735787 6480464 Atenolol results in increased expression of APOB protein CTD PMID:2193493 benazepril multiple interactions ISO RGD:735787 6480464 [valsartan co-treated with benazepril] results in decreased expression of APOB protein; more ... CTD PMID:20671225 bendroflumethiazide affects expression ISO RGD:735787 6480464 Bendroflumethiazide affects the expression of APOB protein CTD PMID:2344503 benzene increases expression ISO RGD:2129 6480464 Benzene results in increased expression of APOB mRNA CTD PMID:15878777 benzo[a]pyrene decreases expression ISO RGD:735787 6480464 Benzo(a)pyrene results in decreased expression of APOB mRNA CTD PMID:20106945 benzo[a]pyrene decreases expression ISO RGD:735787 6480464 Benzo(a)pyrene results in decreased expression of APOB mRNA CTD PMID:20106945 more ... benzo[a]pyrene decreases expression ISO RGD:735787 6480464 Benzo(a)pyrene results in decreased expression of APOB mRNA CTD PMID:20106945 PMID:22316170 beta-D-glucosamine increases degradation ISO RGD:2129 6480464 Glucosamine results in increased degradation of APOB protein CTD PMID:15618547 beta-D-glucosamine multiple interactions ISO RGD:735787 6480464 Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] CTD PMID:15618547 beta-D-glucosamine increases ubiquitination ISO RGD:735787 6480464 Glucosamine results in increased ubiquitination of APOB protein CTD PMID:15618547 beta-D-glucosamine decreases secretion ISO RGD:735787 6480464 Glucosamine results in decreased secretion of APOB protein CTD PMID:15618547 beta-D-glucosamine decreases localization ISO RGD:735787 6480464 Glucosamine results in decreased localization of APOB protein CTD PMID:15618547 beta-D-glucosamine decreases expression ISO RGD:735787 6480464 Glucosamine results in decreased expression of APOB protein CTD PMID:15618547 beta-D-glucosamine multiple interactions ISO RGD:735787 6480464 acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein] CTD PMID:19383982 beta-D-glucosamine multiple interactions ISO RGD:2129 6480464 Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] CTD PMID:15618547 bezafibrate decreases expression ISO RGD:735787 6480464 Bezafibrate results in decreased expression of APOB protein CTD PMID:1323073 PMID:9822092 bezafibrate decreases expression ISO RGD:735787 6480464 Bezafibrate results in decreased expression of APOB protein CTD PMID:1323073 more ... bezafibrate increases expression ISO RGD:2129 6480464 Bezafibrate results in increased expression of APOB protein CTD PMID:9006809 bezafibrate multiple interactions ISO RGD:2129 6480464 [Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form CTD PMID:8944747 bezafibrate decreases expression EXP   6480464 Bezafibrate results in decreased expression of APOB mRNA alternative form CTD PMID:12782154 bezafibrate decreases secretion ISO RGD:735787 6480464 Bezafibrate results in decreased secretion of APOB protein CTD PMID:21640707 bezafibrate multiple interactions EXP   6480464 PPARA protein affects the reaction [Bezafibrate results in decreased expression of APOB mRNA alternative form]; more ... CTD PMID:12782154 bezafibrate decreases expression ISO RGD:735787 6480464 Bezafibrate results in decreased expression of APOB protein CTD PMID:8017468 more ... bezafibrate multiple interactions ISO RGD:735787 6480464 Bezafibrate inhibits the reaction [Oleic Acid results in increased expression of APOB protein] CTD PMID:12048068 bezafibrate decreases expression ISO RGD:735787 6480464 Bezafibrate results in decreased expression of APOB protein CTD PMID:3084275 more ... bezafibrate decreases expression ISO RGD:735787 6480464 Bezafibrate results in decreased expression of APOB protein CTD PMID:9223394 more ... bezafibrate decreases expression ISO RGD:735787 6480464 Bezafibrate results in decreased expression of APOB protein CTD PMID:9822092 PMID:1323073 bisphenol A increases expression ISO RGD:2129 6480464 bisphenol A results in increased expression of APOB mRNA CTD PMID:17010207 bisphenol A decreases expression ISO RGD:2129 6480464 bisphenol A results in decreased expression of APOB mRNA CTD PMID:23399309 bisphenol A multiple interactions ISO RGD:2129 6480464 [bisphenol A results in decreased expression of APOB mRNA] which affects the abundance of Triglycerides; more ... CTD PMID:23399309 caffeine multiple interactions ISO RGD:735787 6480464 [Ephedrine co-treated with Caffeine] results in decreased expression of APOB protein CTD PMID:16324916 capsaicin increases expression ISO RGD:2129 6480464 Capsaicin results in increased expression of APOB mRNA CTD PMID:16278290 cefaloridine increases expression ISO RGD:2129 6480464 Cephaloridine results in increased expression of APOB mRNA CTD PMID:18500788 cholesterol increases expression ISO RGD:2129 6480464 Cholesterol results in increased expression of APOB protein CTD PMID:16271152 PMID:16581047 cholesterol increases expression ISO RGD:2129 6480464 Cholesterol results in increased expression of APOB protein CTD PMID:16581047 PMID:16271152 cholesterol multiple interactions ISO RGD:2129 6480464 Selenium inhibits the reaction [Cholesterol results in increased expression of APOB protein] CTD PMID:16581047 cisplatin increases expression ISO RGD:2129 6480464 Cisplatin results in increased expression of APOB protein CTD PMID:22023808 clofibrate decreases expression EXP   6480464 Clofibrate results in decreased expression of APOB protein CTD PMID:20573577 clofibric acid multiple interactions ISO RGD:2129 6480464 [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form CTD PMID:8944747 copper atom multiple interactions ISO RGD:735787 6480464 Ascorbic Acid promotes the reaction [Quercetin inhibits the reaction [Copper results in increased oxidation of APOB protein]]; more ... CTD PMID:17475462 copper atom increases reduction ISO RGD:735787 6480464 APOB protein results in increased reduction of Copper CTD PMID:11368321 copper atom multiple interactions ISO RGD:735787 6480464 alpha-Tocopherol promotes the reaction [APOB protein results in increased reduction of Copper] CTD PMID:11368321 copper atom increases oxidation ISO RGD:735787 6480464 Copper results in increased oxidation of APOB protein CTD PMID:17475462 copper(0) multiple interactions ISO RGD:735787 6480464 Ascorbic Acid promotes the reaction [Quercetin inhibits the reaction [Copper results in increased oxidation of APOB protein]]; more ... CTD PMID:17475462 copper(0) increases reduction ISO RGD:735787 6480464 APOB protein results in increased reduction of Copper CTD PMID:11368321 copper(0) multiple interactions ISO RGD:735787 6480464 alpha-Tocopherol promotes the reaction [APOB protein results in increased reduction of Copper] CTD PMID:11368321 copper(0) increases oxidation ISO RGD:735787 6480464 Copper results in increased oxidation of APOB protein CTD PMID:17475462 copper(2+) sulfate decreases expression ISO RGD:735787 6480464 Copper Sulfate results in decreased expression of APOB mRNA CTD PMID:19549813 cyclophosphamide decreases expression ISO RGD:2129 6480464 Cyclophosphamide results in decreased expression of APOB mRNA CTD PMID:18246545 cyclosporin A decreases expression ISO RGD:735787 6480464 Cyclosporine results in decreased expression of APOB mRNA CTD PMID:20106945 cyclosporin A decreases expression EXP   6480464 Cyclosporine results in decreased expression of APOB mRNA CTD PMID:19770486 cyclosporin A decreases expression ISO RGD:2129 6480464 Cyclosporine results in decreased expression of APOB mRNA CTD PMID:19224547 cypermethrin increases expression ISO RGD:2129 6480464 cypermethrin results in increased expression of APOB mRNA CTD PMID:9650644 daunorubicin increases expression ISO RGD:2129 6480464 Daunorubicin results in increased expression of APOB protein CTD PMID:7637207 dexamethasone increases expression ISO RGD:2129 6480464 Dexamethasone results in increased expression of APOB protein CTD PMID:15965953 diethyl pyrocarbonate increases metabolic processing ISO RGD:735787 6480464 Diethyl Pyrocarbonate results in increased metabolism of APOB protein CTD PMID:11304478 doxorubicin increases expression ISO RGD:2129 6480464 Doxorubicin results in increased expression of APOB protein CTD PMID:8506949 PMID:8255516 doxorubicin increases expression ISO RGD:2129 6480464 Doxorubicin results in increased expression of APOB protein CTD PMID:8255516 PMID:8506949 elemental selenium multiple interactions ISO RGD:2129 6480464 Selenium inhibits the reaction [Cholesterol results in increased expression of APOB protein] CTD PMID:16581047 elemental selenium decreases expression ISO RGD:2129 6480464 Selenium results in decreased expression of APOB protein CTD PMID:16271152 ethanol multiple interactions EXP   6480464 [Ethanol co-treated with Zinc] results in increased expression of APOB mRNA CTD PMID:19637192 ethanol increases expression ISO RGD:2129 6480464 Ethanol results in increased expression of APOB mRNA CTD PMID:16946407 ethanolamine multiple interactions ISO RGD:2129 6480464 [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form; more ... CTD PMID:8944747 fenofibrate decreases expression ISO RGD:735787 6480464 Fenofibrate results in decreased expression of APOB protein CTD PMID:21411093 ferulic acid decreases expression EXP   6480464 ferulic acid results in decreased expression of APOB protein CTD PMID:20573577 folic acid multiple interactions ISO RGD:735787 6480464 [Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Oleic Acid co-treated with Folic Acid co-treated with Vitamin B 6 co-treated with Vitamin E] results in decreased expression of APOB protein CTD PMID:17237316 folic acid multiple interactions EXP   6480464 [APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased expression of APOB protein CTD PMID:17118406 folic acid increases expression ISO RGD:735787 6480464 Folic Acid results in increased expression of APOB mRNA CTD PMID:17868486 fructose multiple interactions ISO RGD:2129 6480464 atorvastatin inhibits the reaction [Fructose results in increased expression of APOB protein] CTD PMID:12065722 fructose increases expression ISO RGD:2129 6480464 Fructose results in increased expression of APOB protein CTD PMID:8415773 PMID:12065722 fructose increases expression ISO RGD:2129 6480464 Fructose results in increased expression of APOB protein CTD PMID:12065722 PMID:8415773 fructose increases expression ISO RGD:2129 6480464 Fructose results in increased expression of APOB mRNA CTD PMID:8415773 gallic acid decreases secretion ISO RGD:735787 6480464 Gallic Acid results in decreased secretion of APOB protein CTD PMID:12612140 gamma-hexachlorocyclohexane affects expression ISO RGD:2129 6480464 Lindane affects the expression of APOB mRNA CTD PMID:17785943 gemfibrozil decreases expression ISO RGD:735787 6480464 Gemfibrozil results in decreased expression of APOB protein CTD PMID:11701466 gemfibrozil decreases expression ISO RGD:2129 6480464 Gemfibrozil results in decreased expression of APOB protein CTD PMID:9006809 genistein increases expression ISO RGD:2129 6480464 Genistein results in increased expression of APOB mRNA CTD PMID:17010207 hydrogen peroxide affects expression ISO RGD:735787 6480464 Hydrogen Peroxide affects the expression of APOB mRNA CTD PMID:20044591 irbesartan affects response to substance ISO RGD:735787 6480464 APOB gene SNP affects the susceptibility to irbesartan CTD PMID:15453913 PMID:15614026 irbesartan affects response to substance ISO RGD:735787 6480464 APOB gene SNP affects the susceptibility to irbesartan CTD PMID:15614026 PMID:15453913 L-ascorbic acid multiple interactions ISO RGD:735787 6480464 Ascorbic Acid promotes the reaction [Flavonoids inhibits the reaction [Copper results in increased oxidation of APOB protein]]; more ... CTD PMID:17475462 L-ascorbic acid multiple interactions ISO RGD:735787 6480464 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of APOB mRNA CTD PMID:17639512 lactacystin multiple interactions ISO RGD:735787 6480464 acetylleucyl-leucyl-norleucinal inhibits the reaction [lactacystin results in decreased expression of and results in decreased secretion of APOB protein]; more ... CTD PMID:19383982 lactacystin increases secretion ISO RGD:735787 6480464 lactacystin results in increased secretion of APOB protein CTD PMID:15618547 lactacystin increases expression ISO RGD:735787 6480464 lactacystin results in increased expression of APOB protein CTD PMID:15618547 lactacystin multiple interactions ISO RGD:735787 6480464 HSPA5 promotes the reaction [lactacystin results in increased secretion of APOB protein]; more ... CTD PMID:15618547 levonorgestrel multiple interactions ISO RGD:735787 6480464 [Ethinyl Estradiol co-treated with Levonorgestrel] results in increased expression of APOB protein CTD PMID:15769986 lovastatin multiple interactions ISO RGD:735787 6480464 [Niacin co-treated with Lovastatin] results in decreased expression of APOB protein CTD PMID:12633795 lovastatin decreases secretion ISO RGD:735787 6480464 Lovastatin results in decreased secretion of APOB protein CTD PMID:11728391 morphine increases expression ISO RGD:735787 6480464 Morphine results in increased expression of APOB protein CTD PMID:18980684 nicotinic acid multiple interactions ISO RGD:735787 6480464 [Niacin co-treated with Lovastatin] results in decreased expression of APOB protein CTD PMID:12633795 nicotinic acid decreases expression ISO RGD:735787 6480464 Niacin results in decreased expression of APOB protein CTD PMID:15539964 PMID:11701466 nicotinic acid decreases expression ISO RGD:735787 6480464 Niacin results in decreased expression of APOB protein CTD PMID:11701466 PMID:15539964 nicotinic acid multiple interactions ISO RGD:735787 6480464 [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein CTD PMID:18471454 ochratoxin A decreases expression ISO RGD:2129 6480464 ochratoxin A results in decreased expression of APOB mRNA CTD PMID:16251485 ochratoxin A decreases expression ISO RGD:2129 6480464 ochratoxin A results in decreased expression of APOB mRNA CTD PMID:16251485 PMID:19717638 ochratoxin A decreases expression ISO RGD:2129 6480464 ochratoxin A results in decreased expression of APOB mRNA CTD PMID:19717638 PMID:16251485 oleic acid multiple interactions ISO RGD:735787 6480464 [Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Oleic Acid co-treated with Folic Acid co-treated with Vitamin B 6 co-treated with Vitamin E] results in decreased expression of APOB protein CTD PMID:17237316 oleic acid increases expression ISO RGD:735787 6480464 Oleic Acid results in increased expression of APOB protein CTD PMID:12048068 oleic acid multiple interactions ISO RGD:735787 6480464 Bezafibrate inhibits the reaction [Oleic Acid results in increased expression of APOB protein] CTD PMID:12048068 oleic acid multiple interactions ISO RGD:2129 6480464 Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] CTD PMID:15618547 oleic acid multiple interactions ISO RGD:735787 6480464 Oleic Acid results in increased expression of and results in increased secretion of APOB protein CTD PMID:19383982 oleic acid multiple interactions ISO RGD:735787 6480464 Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] CTD PMID:15618547 palmitoyl ethanolamide affects folding ISO RGD:735787 6480464 palmidrol affects the folding of APOB protein CTD PMID:16115474 paracetamol decreases expression ISO RGD:735787 6480464 Acetaminophen results in decreased expression of APOB mRNA CTD PMID:21420995 perfluorooctane-1-sulfonic acid decreases expression EXP   6480464 perfluorooctane sulfonic acid results in decreased expression of APOB mRNA CTD PMID:21705711 perfluorooctanoic acid affects localization ISO RGD:2129 6480464 perfluorooctanoic acid affects the localization of APOB protein CTD PMID:10101272 phenobarbital decreases expression EXP   6480464 Phenobarbital results in decreased expression of APOB mRNA CTD PMID:23091169 pioglitazone decreases expression ISO RGD:735787 6480464 pioglitazone results in decreased expression of APOB protein CTD PMID:16324916 pirinixic acid decreases expression EXP   6480464 pirinixic acid results in decreased expression of APOB protein CTD PMID:15537571 pirinixic acid increases secretion EXP   6480464 pirinixic acid results in increased secretion of APOB protein CTD PMID:16282640 pirinixic acid increases secretion ISO RGD:2129 6480464 pirinixic acid results in increased secretion of APOB protein alternative form CTD PMID:15537571 quercetin multiple interactions ISO RGD:735787 6480464 Ascorbic Acid promotes the reaction [Quercetin inhibits the reaction [Copper results in increased oxidation of APOB protein]]; more ... CTD PMID:17475462 quercetin decreases expression ISO RGD:735787 6480464 Quercetin results in decreased expression of APOB mRNA CTD PMID:21632981 quercetin decreases secretion ISO RGD:735787 6480464 Quercetin results in decreased secretion of APOB protein CTD PMID:12612140 quercetin multiple interactions ISO RGD:735787 6480464 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of APOB mRNA CTD PMID:17639512 rel-(3R,5S)-fluvastatin multiple interactions ISO RGD:735787 6480464 [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin CTD PMID:19773416 rel-(3R,5S)-fluvastatin multiple interactions ISO RGD:735787 6480464 fluvastatin promotes the reaction [[valsartan co-treated with benazepril] results in decreased expression of APOB protein] CTD PMID:20671225 resveratrol decreases secretion ISO RGD:735787 6480464 resveratrol results in decreased secretion of APOB protein CTD PMID:12612140 rosiglitazone increases secretion EXP   6480464 rosiglitazone results in increased secretion of APOB protein CTD PMID:20503262 rosuvastatin decreases expression ISO RGD:735787 6480464 rosuvastatin results in decreased expression of APOB protein CTD PMID:15539964 rosuvastatin decreases expression ISO RGD:735787 6480464 rosuvastatin results in decreased expression of APOB protein CTD PMID:15539964 PMID:18702965 rosuvastatin decreases expression ISO RGD:735787 6480464 rosuvastatin results in decreased expression of APOB protein CTD PMID:18702965 PMID:15539964 selenium atom multiple interactions ISO RGD:2129 6480464 Selenium inhibits the reaction [Cholesterol results in increased expression of APOB protein] CTD PMID:16581047 selenium atom decreases expression ISO RGD:2129 6480464 Selenium results in decreased expression of APOB protein CTD PMID:16271152 simvastatin multiple interactions ISO RGD:735787 6480464 [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein CTD PMID:18471454 simvastatin decreases secretion ISO RGD:735787 6480464 Simvastatin results in decreased secretion of APOB protein CTD PMID:11728391 more ... simvastatin decreases expression ISO RGD:735787 6480464 Simvastatin results in decreased expression of APOB protein CTD PMID:10498134 more ... simvastatin decreases expression ISO RGD:735787 6480464 Simvastatin results in decreased expression of APOB protein CTD PMID:10498134 more ... simvastatin decreases secretion ISO RGD:735787 6480464 Simvastatin results in decreased secretion of APOB protein CTD PMID:1627634 more ... simvastatin decreases expression ISO RGD:735787 6480464 Simvastatin results in decreased expression of APOB protein CTD PMID:12633795 more ... simvastatin decreases secretion ISO RGD:735787 6480464 Simvastatin results in decreased secretion of APOB protein CTD PMID:11728391 more ... simvastatin decreases expression ISO RGD:735787 6480464 Simvastatin results in decreased expression of APOB protein CTD PMID:15184351 more ... simvastatin decreases expression ISO RGD:2129 6480464 Simvastatin results in decreased expression of APOB mRNA CTD PMID:8461338 simvastatin decreases expression ISO RGD:2129 6480464 Simvastatin results in decreased expression of APOB protein CTD PMID:8289597 simvastatin multiple interactions ISO RGD:2129 6480464 Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOB protein] CTD PMID:8461338 simvastatin decreases secretion ISO RGD:735787 6480464 Simvastatin results in decreased secretion of APOB protein CTD PMID:1627634 more ... simvastatin decreases expression ISO RGD:735787 6480464 Simvastatin results in decreased expression of APOB protein CTD PMID:10498134 more ... simvastatin multiple interactions ISO RGD:735787 6480464 HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB] CTD PMID:20413733 simvastatin affects response to substance ISO RGD:735787 6480464 APOB polymorphism affects the susceptibility to Simvastatin CTD PMID:12901521 simvastatin decreases expression ISO RGD:735787 6480464 Simvastatin results in decreased expression of APOB protein CTD PMID:12633795 PMID:15184351 sodium acetate trihydrate multiple interactions ISO RGD:735787 6480464 [Sodium Acetate co-treated with acetic anhydride] results in increased acetylation of APOB protein CTD PMID:11304478 sodium dichromate affects expression ISO RGD:2129 6480464 sodium bichromate affects the expression of APOB mRNA CTD PMID:22110744 tamoxifen decreases expression ISO RGD:2129 6480464 Tamoxifen results in decreased expression of APOB mRNA CTD PMID:19224547 tetrachloromethane decreases expression EXP   6480464 Carbon Tetrachloride results in decreased expression of APOB protein CTD PMID:17405876 tetrachloromethane decreases expression ISO RGD:2129 6480464 Carbon Tetrachloride results in decreased expression of APOB mRNA CTD PMID:16644059 PMID:19224547 tetrachloromethane affects expression ISO RGD:2129 6480464 Carbon Tetrachloride affects the expression of APOB mRNA CTD PMID:15963342 tetrachloromethane decreases expression ISO RGD:2129 6480464 Carbon Tetrachloride results in decreased expression of APOB mRNA CTD PMID:19224547 PMID:16644059 tetracycline decreases expression ISO RGD:2129 6480464 Tetracycline results in decreased expression of APOB mRNA CTD PMID:19224547 trans-resveratrol decreases secretion ISO RGD:735787 6480464 resveratrol results in decreased secretion of APOB protein CTD PMID:12612140 trichloroethene decreases expression EXP   6480464 Trichloroethylene results in decreased expression of APOB mRNA CTD PMID:19448997 valsartan multiple interactions ISO RGD:735787 6480464 fluvastatin promotes the reaction [[valsartan co-treated with benazepril] results in decreased expression of APOB protein] CTD PMID:20671225 wortmannin multiple interactions ISO RGD:2129 6480464 wortmannin inhibits the reaction [bisphenol A results in decreased expression of APOB mRNA]; more ... CTD PMID:23399309 zinc atom multiple interactions ISO RGD:735787 6480464 Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of APOB protein] CTD PMID:19637192 zinc atom decreases expression ISO RGD:2129 6480464 Zinc deficiency results in decreased expression of APOB protein modified form CTD PMID:10498758 zinc atom multiple interactions EXP   6480464 [Ethanol co-treated with Zinc] results in increased expression of APOB mRNA CTD PMID:19637192 zinc atom affects expression ISO RGD:2129 6480464 Zinc deficiency affects the expression of APOB mRNA modified form CTD PMID:10498758 zinc(0) affects expression ISO RGD:2129 6480464 Zinc deficiency affects the expression of APOB mRNA modified form CTD PMID:10498758 zinc(0) multiple interactions EXP   6480464 [Ethanol co-treated with Zinc] results in increased expression of APOB mRNA CTD PMID:19637192 zinc(0) multiple interactions ISO RGD:735787 6480464 Zinc inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of APOB protein] CTD PMID:19637192 zinc(0) decreases expression ISO RGD:2129 6480464 Zinc deficiency results in decreased expression of APOB protein modified form CTD PMID:10498758 Gene Ontology Annotations Biological Process Term Qualifier Evidence With Reference Notes Source Original Reference(s) artery morphogenesis   IGI MGI:MGI:88057 2290270 MGI:MGI:3695082|PMID:16230502 MGI MGI:MGI:3695082 PMID:16230502 cholesterol efflux   IGI MGI:MGI:104539 2290270 MGI:MGI:5428098|PMID:22363685 MGI MGI:MGI:5428098 PMID:22363685 cholesterol homeostasis   IMP MGI:MGI:1857625 2290270 MGI:MGI:71076|PMID:7878058 MGI MGI:MGI:71076 PMID:7878058 cholesterol homeostasis   IGI MGI:MGI:88057 2290270 MGI:MGI:3695082|PMID:16230502 MGI MGI:MGI:3695082 PMID:16230502 cholesterol homeostasis   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 cholesterol homeostasis   IMP MGI:MGI:1857304 2290270 MGI:MGI:1201298|PMID:9502790 MGI MGI:MGI:1201298 PMID:9502790 cholesterol homeostasis   IGI MGI:MGI:88057|MGI:MGI:96765 2290270 MGI:MGI:1928445|PMID:11120757 MGI MGI:MGI:1928445 PMID:11120757 cholesterol homeostasis   IMP MGI:MGI:1857304|MGI:MGI:1857303 2290270 MGI:MGI:893988|PMID:9202070 MGI MGI:MGI:893988 PMID:9202070 cholesterol homeostasis   IMP MGI:MGI:2157108 2290270 MGI:MGI:1316893|PMID:9852051 MGI MGI:MGI:1316893 PMID:9852051 cholesterol homeostasis   IMP MGI:MGI:3665449 2290270 MGI:MGI:83856|PMID:8921909 MGI MGI:MGI:83856 PMID:8921909 cholesterol metabolic process   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 cholesterol transport   IMP MGI:MGI:2157090 2290270 MGI:MGI:77225|PMID:7593600 MGI MGI:MGI:77225 PMID:7593600 cholesterol transport   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 fertilization   IMP MGI:MGI:2157090 2290270 MGI:MGI:83280|PMID:8855280 MGI MGI:MGI:83280 PMID:8855280 in utero embryonic development   IMP MGI:MGI:2157775 2290270 MGI:MGI:1201298|PMID:9502790 MGI MGI:MGI:1201298 PMID:9502790 in utero embryonic development   IMP MGI:MGI:1857625 2290270 MGI:MGI:71076|PMID:7878058 MGI MGI:MGI:71076 PMID:7878058 lipid catabolic process   IMP MGI:MGI:2183298 2290270 MGI:MGI:3652707|PMID:16455790 MGI MGI:MGI:3652707 PMID:16455790 lipid metabolic process   IDA   2290270 MGI:MGI:2386141|PMID:12072432 MGI MGI:MGI:2386141 PMID:12072432 lipid metabolic process   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 lipid metabolic process   IMP MGI:MGI:2183298 2290270 MGI:MGI:3612778|PMID:15790761 MGI MGI:MGI:3612778 PMID:15790761 lipid metabolic process   IGI MGI:MGI:88057|MGI:MGI:96765 2290270 MGI:MGI:1928445|PMID:11120757 MGI MGI:MGI:1928445 PMID:11120757 lipid metabolic process   IMP MGI:MGI:1857141 2290270 MGI:MGI:64433|PMID:8460149 MGI MGI:MGI:64433 PMID:8460149 lipid transport   IEA UniProtKB-KW:KW-0445 2290270 MGI:MGI:1354194 UniProtKB MGI:MGI:1354194 lipid transport   IEA InterPro:IPR015819|InterPro:IPR001747|InterPro:IPR009454|InterPro:IPR015816|InterPro:IPR015255|InterPro:IPR015817|InterPro:IPR015818|InterPro:IPR011030 2290270 MGI:MGI:2152098 UniProtKB MGI:MGI:2152098 lipoprotein biosynthetic process   IGI MGI:MGI:103298 2290270 MGI:MGI:3028770|PMID:13130124 MGI MGI:MGI:3028770 PMID:13130124 lipoprotein catabolic process   IGI MGI:MGI:107202 2290270 MGI:MGI:3588634|PMID:15863839 MGI MGI:MGI:3588634 PMID:15863839 lipoprotein metabolic process   IMP MGI:MGI:1857625 2290270 MGI:MGI:71076|PMID:7878058 MGI MGI:MGI:71076 PMID:7878058 lipoprotein metabolic process   IGI MGI:MGI:88057 2290270 MGI:MGI:3028770|PMID:13130124 MGI MGI:MGI:3028770 PMID:13130124 lipoprotein metabolic process   IGI MGI:MGI:88057|MGI:MGI:96765 2290270 MGI:MGI:1928445|PMID:11120757 MGI MGI:MGI:1928445 PMID:11120757 lipoprotein metabolic process   IMP MGI:MGI:3665449 2290270 MGI:MGI:3664699|PMID:10705993 MGI MGI:MGI:3664699 PMID:10705993 lipoprotein metabolic process   IGI MGI:MGI:96765 2290270 MGI:MGI:3028770|PMID:13130124 MGI MGI:MGI:3028770 PMID:13130124 lipoprotein metabolic process   IMP MGI:MGI:1857303 2290270 MGI:MGI:1354526|PMID:10713055 MGI MGI:MGI:1354526 PMID:10713055 lipoprotein metabolic process   IMP MGI:MGI:2157108 2290270 MGI:MGI:1316893|PMID:9852051 MGI MGI:MGI:1316893 PMID:9852051 lipoprotein transport   IMP MGI:MGI:2183298 2290270 MGI:MGI:3028770|PMID:13130124 MGI MGI:MGI:3028770 PMID:13130124 lipoprotein transport   IGI MGI:MGI:103298 2290270 MGI:MGI:3028770|PMID:13130124 MGI MGI:MGI:3028770 PMID:13130124 low-density lipoprotein particle clearance   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 low-density lipoprotein particle remodeling   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 nervous system development   IMP MGI:MGI:1857625 2290270 MGI:MGI:71076|PMID:7878058 MGI MGI:MGI:71076 PMID:7878058 nervous system development   IMP MGI:MGI:3665449 2290270 MGI:MGI:83856|PMID:8921909 MGI MGI:MGI:83856 PMID:8921909 nervous system development   IMP MGI:MGI:2157775 2290270 MGI:MGI:1201298|PMID:9502790 MGI MGI:MGI:1201298 PMID:9502790 positive regulation of cholesterol storage   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 positive regulation of lipid storage   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 positive regulation of macrophage derived foam cell differentiation   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 post-embryonic development   IMP MGI:MGI:2157108 2290270 MGI:MGI:1316893|PMID:9852051 MGI MGI:MGI:1316893 PMID:9852051 regulation of cholesterol biosynthetic process   IMP MGI:MGI:2183298 2290270 MGI:MGI:3652707|PMID:16455790 MGI MGI:MGI:3652707 PMID:16455790 response to carbohydrate stimulus   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 sperm motility   IMP MGI:MGI:2157090 2290270 MGI:MGI:83280|PMID:8855280 MGI MGI:MGI:83280 PMID:8855280 spermatogenesis   IMP MGI:MGI:2157090 2290270 MGI:MGI:83280|PMID:8855280 MGI MGI:MGI:83280 PMID:8855280 steroid metabolic process   IEA UniProtKB-KW:KW-0753 2290270 MGI:MGI:1354194 UniProtKB MGI:MGI:1354194 transport   IEA UniProtKB-KW:KW-0813 2290270 MGI:MGI:1354194 UniProtKB MGI:MGI:1354194 triglyceride catabolic process   IMP MGI:MGI:2183298 2290270 MGI:MGI:3652707|PMID:16455790 MGI MGI:MGI:3652707 PMID:16455790 triglyceride catabolic process   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 triglyceride mobilization   IMP MGI:MGI:2183298 2290270 MGI:MGI:1913181|PMID:10893242 MGI MGI:MGI:1913181 PMID:10893242 Cellular Component Term Qualifier Evidence With Reference Notes Source Original Reference(s) chylomicron   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 cytoplasm   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 endoplasmic reticulum   IDA   2290270 MGI:MGI:2386141|PMID:12072432 MGI MGI:MGI:2386141 PMID:12072432 extracellular region   IEA UniProtKB-KW:KW-0964 2290270 MGI:MGI:1354194 UniProtKB MGI:MGI:1354194 extracellular space   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 intermediate-density lipoprotein particle   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 intracellular membrane-bounded organelle   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 low-density lipoprotein particle   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 mature chylomicron   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 very-low-density lipoprotein particle   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 very-low-density lipoprotein particle   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 vesicle lumen   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 vesicle membrane   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 Molecular Function Term Qualifier Evidence With Reference Notes Source Original Reference(s) cholesterol transporter activity   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 enzyme binding   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 heparin binding   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 lipid binding   ISO UniProtKB:Q7TMA5 2290270 MGI:MGI:4417868 RGD MGI:MGI:4417868 lipid transporter activity   IEA InterPro:IPR015819|InterPro:IPR001747|InterPro:IPR009454|InterPro:IPR015816|InterPro:IPR015255|InterPro:IPR015817|InterPro:IPR015818|InterPro:IPR011030 2290270 MGI:MGI:2152098 UniProtKB MGI:MGI:2152098 low-density lipoprotein particle receptor binding   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 phospholipid binding   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 protein heterodimerization activity   ISO UniProtKB:P04114 2290270 MGI:MGI:4834177 MGI MGI:MGI:4834177 Molecular Pathway Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) altered lipoprotein metabolic pathway   ISS   1578416   RGD   forkhead class A signaling pathway   ISO RGD:735787 6484113   PID PID:200226 lipoprotein metabolic pathway   ISS   1578416   RGD   External Database Links KEGG Pathway Fat digestion and absorption Vitamin digestion and absorption Pathway Interaction Database amb2 Integrin signaling (PID:200127) FOXA1 transcription factor network (PID:200226) Phenotype Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) abnormal blood homeostasis   IAGP   5509061   MGI PMID:8921909 abnormal blood homeostasis   IAGP   5509061   MGI PMID:10705993 abnormal cholesterol homeostasis   IAGP   5509061   MGI PMID:7878058 abnormal circulating cholesterol level   IAGP   5509061   MGI PMID:8460149 abnormal circulating HDL cholesterol level   IAGP   5509061   MGI PMID:8921909 abnormal embryogenesis/ development   IAGP   5509061   MGI PMID:9026532 abnormal eye electrophysiology   IAGP   5509061   MGI PMID:18385042 abnormal retinal pigment epithelium morphology   IAGP   5509061   MGI PMID:18385042 abnormal triglyceride level   IAGP   5509061   MGI PMID:10705993 abnormal triglyceride level   IAGP   5509061   MGI PMID:8460149 abnormal visceral yolk sac morphology   IAGP   5509061   MGI PMID:9026532 asthenozoospermia   IAGP   5509061   MGI PMID:8855280 atherosclerotic lesions   IAGP   5509061   MGI PMID:17872464 complete prenatal lethality   IAGP   5509061   MGI PMID:7593600 complete prenatal lethality   IAGP   5509061   MGI PMID:9502790 decreased circulating cholesterol level   IAGP   5509061   MGI PMID:8921909 decreased circulating cholesterol level   IAGP   5509061   MGI PMID:9502790 decreased circulating cholesterol level   IAGP   5509061   MGI PMID:11839763 decreased circulating cholesterol level   IAGP   5509061   MGI PMID:7878058 decreased circulating cholesterol level   IAGP   5509061   MGI PMID:10705993 decreased circulating HDL cholesterol level   IAGP   5509061   MGI PMID:7878058 decreased circulating HDL cholesterol level   IAGP   5509061   MGI PMID:11839763 decreased circulating HDL cholesterol level   IAGP   5509061   MGI PMID:10893242 decreased circulating HDL cholesterol level   IAGP   5509061   MGI PMID:8460149 decreased circulating LDL cholesterol level   IAGP   5509061   MGI PMID:8921909 decreased circulating LDL cholesterol level   IAGP   5509061   MGI PMID:11839763 decreased circulating LDL cholesterol level   IAGP   5509061   MGI PMID:9852051 decreased circulating LDL cholesterol level   IAGP   5509061   MGI PMID:10893242 decreased circulating LDL cholesterol level   IAGP   5509061   MGI PMID:8692825 decreased circulating triglyceride level   IAGP   5509061   MGI PMID:8692825 decreased circulating triglyceride level   IAGP   5509061   MGI PMID:11839763 decreased circulating triglyceride level   IAGP   5509061   MGI PMID:10893242 decreased circulating VLDL cholesterol level   IAGP   5509061   MGI PMID:8921909 decreased circulating VLDL cholesterol level   IAGP   5509061   MGI PMID:11839763 decreased circulating VLDL cholesterol level   IAGP   5509061   MGI PMID:9852051 decreased circulating VLDL cholesterol level   IAGP   5509061   MGI PMID:10893242 decreased embryo size   IAGP   5509061   MGI PMID:9502790 exencephaly   IAGP   5509061   MGI PMID:8921909 exencephaly   IAGP   5509061   MGI PMID:9502790 exencephaly   IAGP   5509061   MGI PMID:8460149 exencephaly   IAGP   5509061   MGI PMID:7597652 exencephaly   IAGP   5509061   MGI PMID:7878058 hemorrhage   IAGP   5509061   MGI PMID:9502790 hepatic steatosis   IAGP   5509061   MGI PMID:10893242 hepatic steatosis   IAGP   5509061   MGI PMID:11839763 herniated liver   IAGP   5509061   MGI PMID:9502790 hydroencephaly   IAGP   5509061   MGI PMID:8921909 hydroencephaly   IAGP   5509061   MGI PMID:8460149 hydroencephaly   IAGP   5509061   MGI PMID:7597652 impaired acrosome reaction   IAGP   5509061   MGI PMID:8855280 impaired glucose tolerance   IAGP   5509061   MGI PMID:17872464 increased circulating glucose level   IAGP   5509061   MGI PMID:17872464 increased circulating insulin level   IAGP   5509061   MGI PMID:17872464 increased circulating LDL cholesterol level   IAGP   5509061   MGI PMID:8692825 increased circulating triglyceride level   IAGP   5509061   MGI PMID:8692825 oligozoospermia   IAGP   5509061   MGI PMID:8855280 partial embryonic lethality during organogenesis   IAGP   5509061   MGI PMID:7878058 partial prenatal lethality   IAGP   5509061   MGI PMID:10893242 partial prenatal lethality   IAGP   5509061   MGI PMID:11839763 postnatal lethality   IAGP   5509061   MGI PMID:9852051 reduced male fertility   IAGP   5509061   MGI PMID:8855280 Disease Annotations Aortic Valve Stenosis  (ISS) Arteriosclerosis  (ISS) Bile Duct Neoplasms  (ISS) Cerebral Infarction  (ISS) Common Bile Duct Neoplasms  (ISS) Coronary Artery Disease  (ISS) Death  (ISS) Death, Sudden, Cardiac  (ISS) Diabetes Mellitus  (ISS) Diabetes Mellitus, Experimental  (ISS) Diabetes Mellitus, Type 1  (ISS) Diabetes Mellitus, Type 2  (ISS) Diabetic Nephropathies  (ISS) Diabetic Retinopathy  (ISS) Endotoxemia  (ISS) Fatty Liver  (ISS) Gallbladder Neoplasms  (ISS) Hypercholesterolemia  (ISS) HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B  (ISS) Hyperlipidemia, Familial Combined  (ISS) Hyperlipidemias  (ISS) Hyperlipoproteinemia Type II  (ISS) Hypobetalipoproteinemias  (ISS) Metabolic Syndrome X  (ISS) Myocardial Ischemia  (ISS) Obesity  (IEP) Gene-Chemical Interaction Annotations (+)-alpha-tocopherol  (ISO) (+)-taxifolin  (ISO) (-)-ephedrine  (ISO) (3S,5R)-fluvastatin  (ISO) 17alpha-ethynylestradiol  (EXP,ISO) 17beta-estradiol  (ISO) 2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO) 2,4,6-trinitrobenzenesulfonic acid  (EXP) 2,4-dinitrotoluene  (ISO) 2,6-dinitrotoluene  (ISO) 2-amino-2-deoxy-D-glucopyranose  (ISO) 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (ISO) acetic anhydride  (ISO) acetylleucyl-leucyl-norleucinal  (ISO) aflatoxin B1  (ISO) aldehydo-D-glucosamine  (ISO) aluminium atom  (ISO) aluminium(0)  (ISO) ammonium chloride  (ISO) Aroclor 1254  (ISO) atenolol  (ISO) benazepril  (ISO) bendroflumethiazide  (ISO) benzene  (ISO) benzo[a]pyrene  (ISO) beta-D-glucosamine  (ISO) bezafibrate  (EXP,ISO) bisphenol A  (ISO) caffeine  (ISO) capsaicin  (ISO) cefaloridine  (ISO) cholesterol  (ISO) cisplatin  (ISO) clofibrate  (EXP) clofibric acid  (ISO) copper atom  (ISO) copper(0)  (ISO) copper(2+) sulfate  (ISO) cyclophosphamide  (ISO) cyclosporin A  (EXP,ISO) cypermethrin  (ISO) daunorubicin  (ISO) dexamethasone  (ISO) diethyl pyrocarbonate  (ISO) doxorubicin  (ISO) elemental selenium  (ISO) ethanol  (EXP,ISO) ethanolamine  (ISO) fenofibrate  (ISO) ferulic acid  (EXP) folic acid  (EXP,ISO) fructose  (ISO) gallic acid  (ISO) gamma-hexachlorocyclohexane  (ISO) gemfibrozil  (ISO) genistein  (ISO) hydrogen peroxide  (ISO) irbesartan  (ISO) L-ascorbic acid  (ISO) lactacystin  (ISO) levonorgestrel  (ISO) lovastatin  (ISO) morphine  (ISO) nicotinic acid  (ISO) ochratoxin A  (ISO) oleic acid  (ISO) palmitoyl ethanolamide  (ISO) paracetamol  (ISO) perfluorooctane-1-sulfonic acid  (EXP) perfluorooctanoic acid  (ISO) phenobarbital  (EXP) pioglitazone  (ISO) pirinixic acid  (EXP,ISO) quercetin  (ISO) rel-(3R,5S)-fluvastatin  (ISO) resveratrol  (ISO) rosiglitazone  (EXP) rosuvastatin  (ISO) selenium atom  (ISO) simvastatin  (ISO) sodium acetate trihydrate  (ISO) sodium dichromate  (ISO) tamoxifen  (ISO) tetrachloromethane  (EXP,ISO) tetracycline  (ISO) trans-resveratrol  (ISO) trichloroethene  (EXP) valsartan  (ISO) wortmannin  (ISO) zinc atom  (EXP,ISO) zinc(0)  (EXP,ISO) Gene Ontology Annotations Biological Process artery morphogenesis  (IGI) cholesterol efflux  (IGI) cholesterol homeostasis  (IGI,IMP,ISO) cholesterol metabolic process  (ISO) cholesterol transport  (IMP,ISO) fertilization  (IMP) in utero embryonic development  (IMP) lipid catabolic process  (IMP) lipid metabolic process  (IDA,IGI,IMP,ISO) lipid transport  (IEA) lipoprotein biosynthetic process  (IGI) lipoprotein catabolic process  (IGI) lipoprotein metabolic process  (IGI,IMP) lipoprotein transport  (IGI,IMP) low-density lipoprotein particle clearance  (ISO) low-density lipoprotein particle remodeling  (ISO) nervous system development  (IMP) positive regulation of cholesterol storage  (ISO) positive regulation of lipid storage  (ISO) positive regulation of macrophage derived foam cell differentiation  (ISO) post-embryonic development  (IMP) regulation of cholesterol biosynthetic process  (IMP) response to carbohydrate stimulus  (ISO) sperm motility  (IMP) spermatogenesis  (IMP) steroid metabolic process  (IEA) transport  (IEA) triglyceride catabolic process  (IMP,ISO) triglyceride mobilization  (IMP) Cellular Component chylomicron  (ISO) cytoplasm  (ISO) endoplasmic reticulum  (IDA) extracellular region  (IEA) extracellular space  (ISO) intermediate-density lipoprotein particle  (ISO) intracellular membrane-bounded organelle  (ISO) low-density lipoprotein particle  (ISO) mature chylomicron  (ISO) very-low-density lipoprotein particle  (ISO) vesicle lumen  (ISO) vesicle membrane  (ISO) Molecular Function cholesterol transporter activity  (ISO) enzyme binding  (ISO) heparin binding  (ISO) lipid binding  (ISO) lipid transporter activity  (IEA) low-density lipoprotein particle receptor binding  (ISO) phospholipid binding  (ISO) protein heterodimerization activity  (ISO) Molecular Pathway Annotations altered lipoprotein metabolic pathway  (ISS) forkhead class A signaling pathway  (ISO) lipoprotein metabolic pathway  (ISS) External Database Links KEGG Pathway Fat digestion and absorption Vitamin digestion and absorption Pathway Interaction Database amb2 Integrin signaling (PID:200127) FOXA1 transcription factor network (PID:200226) Phenotype Annotations abnormal blood homeostasis  (IAGP) abnormal cholesterol homeostasis  (IAGP) abnormal circulating cholesterol level  (IAGP) abnormal circulating HDL cholesterol level  (IAGP) abnormal embryogenesis/ development  (IAGP) abnormal eye electrophysiology  (IAGP) abnormal retinal pigment epithelium morphology  (IAGP) abnormal triglyceride level  (IAGP) abnormal visceral yolk sac morphology  (IAGP) asthenozoospermia  (IAGP) atherosclerotic lesions  (IAGP) complete prenatal lethality  (IAGP) decreased circulating cholesterol level  (IAGP) decreased circulating HDL cholesterol level  (IAGP) decreased circulating LDL cholesterol level  (IAGP) decreased circulating triglyceride level  (IAGP) decreased circulating VLDL cholesterol level  (IAGP) decreased embryo size  (IAGP) exencephaly  (IAGP) hemorrhage  (IAGP) hepatic steatosis  (IAGP) herniated liver  (IAGP) hydroencephaly  (IAGP) impaired acrosome reaction  (IAGP) impaired glucose tolerance  (IAGP) increased circulating glucose level  (IAGP) increased circulating insulin level  (IAGP) increased circulating LDL cholesterol level  (IAGP) increased circulating triglyceride level  (IAGP) oligozoospermia  (IAGP) partial embryonic lethality during organogenesis  (IAGP) partial prenatal lethality  (IAGP) postnatal lethality  (IAGP) reduced male fertility  (IAGP) References - curated 1. Abifadel M, etal., Nat Genet. 2003 Jun;34(2):154-6. 2. al Muhtaseb N, etal., Pediatrics. 1992 May;89(5 Pt 1):936-41. 3. Andreotti G, etal., Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):525-34. Epub 2008 Feb 22. 4. Andreotti G, etal., Int J Cancer. 2008 May 15;122(10):2322-9. 5. Aspichueta P, etal., J Endotoxin Res. 2006;12(3):181-92. 6. Avakian SD, etal., Clin Genet. 2001 Nov;60(5):381-4. 7. Baez S, etal., World J Gastroenterol. 2010 Jan 21;16(3):372-8. 8. Bartels ED, etal., Eur J Clin Invest. 2009 Mar;39(3):190-9. 9. Clarke MW, etal., Clin Chem. 2006 Jul;52(7):1339-45. Epub 2006 May 25. 10. Corella D and Ordovas JM, Annu Rev Nutr. 2005;25:341-90. 11. Dhingra S and Bansal MP, Chem Biol Interact. 2006 May 15;161(1):49-56. Epub 2006 Apr 3. 12. Fredrikson GN, etal., Diabetologia. 2009 Jul;52(7):1426-33. Epub 2009 May 12. 13. Gaffney D, etal., Arterioscler Thromb Vasc Biol. 1995 Aug;15(8):1025-9. 14. Griffin JL, etal., J Proteome Res. 2007 Jan;6(1):54-61. 15. Helio T, etal., J Intern Med. 1992 Jan;231(1):49-57. 16. Konemori G, etal., Nippon Ronen Igakkai Zasshi. 1990 Jan;27(1):22-7. 17. Lally S, etal., Metabolism. 2007 Mar;56(3):430-8. 18. MGD and Homologene mouse data transfer 19. MGD data from the GO Consortium 20. MGD IEA 21. Mulvihill EE, etal., Diabetes. 2009 Oct;58(10):2198-210. Epub 2009 Jul 10. 22. Nakajima K, etal., Atherosclerosis. 2006 Oct 10;. 23. Niemi J, etal., Ann Med. 2009 May 1:1-11. 24. Pan JP, etal., J Formos Med Assoc. 1998 Apr;97(4):233-8. 25. Pandey SN, etal., Liver Int. 2007 Sep;27(7):1008-15. 26. Pei WD, etal., Int J Cardiol. 2007 Feb 14;115(3):293-6. Epub 2006 Jun 22. 27. Pei WD, etal., Int J Cardiol. 2007 Mar 20;116(2):194-200. Epub 2006 Jul 10. 28. Pipeline to import Pathway Interaction Database annotations from NCI into RGD 29. RGD automated import pipeline 30. RGD automated import pipeline for gene-chemical interactions 31. RGD Automated Pipelines 32. Soutar AK and Naoumova RP, Nat Clin Pract Cardiovasc Med. 2007 Apr;4(4):214-25. 33. Su JW, etal., Diabetes Care. 2009 Feb;32(2):e21. 34. Tseng CH Clin Biochem. 2009 Jul;42(10-11):1019-24. Epub 2009 Mar 24. 35. Tybjaerg-Hansen A, etal., N Engl J Med. 1998 May 28;338(22):1577-84. 36. Warden CH, etal., Genomics 1993 Nov;18(2):295-307. 37. West NA, etal., Diabetes Care. 2009 Jan;32(1):175-80. Epub 2008 Oct 22. 38. Young SG, etal., J Clin Invest. 1987 Jun;79(6):1842-51. References - uncurated PubMed 10064308   10064312   10349636   10393218   10553000   10588944   10656920   10705993   10713055   10744773   10859308   10893242   10922068   10926756   11002334   11042159   11076861   11120757   11208732   11217851   11331277   11389586   11420610   11544199   11598138   11839763   11884293   12016514   12040188   12072432   12235184   12466851   12477932   12493769   12615667   12628954   12816761   13130124   1352323   14634011   14679168   1479285   15024002   15105414   15124019   15265030   15342689   15480992   15654123   15766748   15790761   15863839   15904874   16055734   16109169   16129816   16141072   16141073   16175613   16230502   16343994   16380418   16455790   16461842   16498401   16798720   16920700   16921198   16957181   17431188   17496333   17702862   17720994   17872464   17983586   18006607   18160459   18252207   18272520   18369455   18385042   18497885   18502767   18519977   18617647   18645210   18722179   18794388   19020660   19026012   19386592   19433756   19460358   19513531   19542564   1971301   19815815   19834103   19845970   20080679   20231283   20541607   20609438   21267068   21339485   21372297   21398511   21533112   21546607   21562077   2166832   21677750   21778422   21779326   21784065   21826528   22100249   22144466   22144566   22209213   22212222   22363685   22580899   22751103   23029362   2332175   2575591   2627199   3034900   6099394   7593600   7597652   7658156   7671812   7677778   7733512   7741021   7803821   7878058   8044422   8170356   8254057   8409768   8460149   8499655   8631881   8662599   8672142   8675665   8692825   8798769   8827514   8833235   8833906   8855280   8921909   8995758   9026532   9202070   9226457   9494081   9502790   9507992   9539774   9598327   9633945   9717714   9788969   9799833   9832509   9852051 RGD Disease Portals Apob has been annotated in the following RGD Disease Portals. Biological Process Cancer Diseases Cancer Pathways Biological Process Cardiovascular Diseases Cardiovascular Pathways Cardiovascular Phenotypes Biological Process Diabetes Diseases Diabetes Pathways Diabetes Phenotypes Immune and Inflammatory Diseases Immune and Inflammatory Pathways Neurological Diseases Neurological Pathways Neurological Phenotypes Biological Process Obesity Diseases Obesity Pathways Obesity Phenotypes Respiratory Pathways Genomics Comparative Map Data Apob   (Mus musculus) Map Chr Position Strand Source Mouse Genome Assembly GRCm38 12 7,977,677 - 8,016,839 + NCBI Mouse cM Map 12 3.53   NCBI Mouse Celera Assembly 12 8,374,429 - 8,411,685 + NCBI Mouse Genome Assembly Build 37 12 7,984,483 - 8,023,645 + NCBI Mouse Genome Assembly Build 36.1 12 8,017,208 - 8,023,641 + NCBI Mouse Cytogenetic Map 12 A1.1   NCBI APOB   (Homo sapiens) Map Chr Position Strand Source Human Alternate Assembly CHM1_1 2 21,141,971 - 21,184,617 - NCBI Human Genome Assembly HuRef 2 20,956,976 - 20,999,627 - NCBI Human Genome Assembly GRCh37 2 21,224,301 - 21,266,945 - NCBI Human Genome Assembly Build 36 2 21,077,806 - 21,120,450 - NCBI Human Cytogenetic Map 2 p24-p23   NCBI Human Genome Assembly 2 21,135,952 - 21,178,597   NCBI Apob   (Rattus norvegicus) Map Chr Position Strand Source Rat Cytogenetic Map 6 q14   NCBI RGSC Genome Assembly v5.0 6 42,956,372 - 42,995,922 + NCBI RGSC Genome Assembly v3.4 6 31,508,060 - 31,548,083 + NCBI Rat Celera Assembly 6 30,299,724 - 30,339,330 + NCBI Genome Assembly 3.1 6 31,546,139 - 31,550,758 + NCBI Position Markers AI315052   Map Chr Position Strand Source Mouse Genome Assembly GRCm38 12 8,015,759 - 8,015,964   UniSTS Mouse Whitehead/MRC_RH 12 112.01   UniSTS Mouse Celera Assembly 12 8,410,605 - 8,410,810   UniSTS Mouse Genome Assembly Build 37 12 8,022,565 - 8,022,770   UniSTS Mouse Cytogenetic Map 12 A1.1   UniSTS UniSTS:236804   Map Chr Position Strand Source Mouse Genome Assembly GRCm38 12 8,016,031 - 8,016,150   UniSTS Mouse Celera Assembly 12 8,410,877 - 8,410,996   UniSTS Mouse Genome Assembly Build 37 12 8,022,837 - 8,022,956   UniSTS Mouse Cytogenetic Map 12 A1.1   UniSTS Apob   Map Chr Position Strand Source Mouse Genome Assembly GRCm38 12 7,976,776 - 7,976,905   UniSTS Mouse cM Map 12 2.0   UniSTS Mouse Celera Assembly 12 8,373,528 - 8,373,657   UniSTS Mouse Genome Assembly Build 37 12 7,983,582 - 7,983,711   UniSTS Mouse Cytogenetic Map 12 A1.1   UniSTS PMC316377P5   Map Chr Position Strand Source Mouse Genome Assembly GRCm38 12 8,009,846 - 8,010,152   UniSTS Mouse Celera Assembly 12 8,404,691 - 8,404,997   UniSTS Mouse Genome Assembly Build 37 12 8,016,652 - 8,016,958   UniSTS Mouse Cytogenetic Map 12 A1.1   UniSTS Apob   Map Chr Position Strand Source Mouse Genome Assembly GRCm38 12 8,004,979 - 8,005,798   UniSTS Mouse Celera Assembly 12 8,399,824 - 8,400,643   UniSTS Mouse Genome Assembly Build 37 12 8,011,785 - 8,012,604   UniSTS Mouse Cytogenetic Map 12 A1.1   UniSTS QTLs in Region (Mouse Genome Assembly Build 37) The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer RGD ID Symbol Name LOD P Value Trait Sub Trait Chr Start Stop Species 1301143 Skull17_m skull morphology 17 (mouse) Not determined 12 1 22375385 Mouse 1301393 Dyscalc3_m dystrophic cardiac calcinosis 3 (mouse) Not determined 12 1 22375385 Mouse 1559009 Vacq7_m voluntary alcohol consumption QTL 7 (mouse) Not determined 12 1 22375385 Mouse 4142234 Tmc1m3_m Tmc1 modifier 3 (mouse) Not determined 12 1 22375385 Mouse 1357785 Cinda2_m cytokine induced activation 2 (mouse) Not determined 12 1 22375385 Mouse 1301655 Bmd12_m bone mineral density 12 (mouse) Not determined 12 1 24619503 Mouse 1357519 Vtbt12_m vertebral trabecular bone trait 12 (mouse) Not determined 12 1 24619503 Mouse 4141112 Tglq2a_m triglyceride QTL 2a (mouse) Not determined 12 1 27877539 Mouse 4141436 Chldq7_m cholesterol and HDL QTL 7 (mouse) Not determined 12 1 27877539 Mouse 4141713 Pltq3_m platelet quantitative locus 3 (mouse) Not determined 12 1 27877539 Mouse 4142163 Ascla5_m atherosclerotic lesion area 5 (mouse) Not determined 12 1 31353819 Mouse 1301207 Circp1_m circadian photosensitivity 1 (mouse) Not determined 12 1 33387144 Mouse 4141660 Nbwa1_m NZB and NZW autoimmunity 1 (mouse) Not determined 12 296939 34297107 Mouse 1301574 Lmblgq5_m limb length QTL 5 (mouse) Not determined 12 553252 34553422 Mouse Sequence Nucleotide Sequences Nucleotide RefSeqs NM_009693 (Get FASTA) Search GEO for Microarray Profiles GenBank Nucleotide AAHY01097293 (Get FASTA) Search GEO for Microarray Profiles   AAHY01097294 (Get FASTA) Search GEO for Microarray Profiles   AC163900 (Get FASTA) Search GEO for Microarray Profiles   AF187728 (Get FASTA) Search GEO for Microarray Profiles   AI324120 (Get FASTA) Search GEO for Microarray Profiles   AK147540 (Get FASTA) Search GEO for Microarray Profiles   AK160920 (Get FASTA) Search GEO for Microarray Profiles   BC028880 (Get FASTA) Search GEO for Microarray Profiles   BC038263 (Get FASTA) Search GEO for Microarray Profiles   BC100607 (Get FASTA) Search GEO for Microarray Profiles   BC141357 (Get FASTA) Search GEO for Microarray Profiles   BC141360 (Get FASTA) Search GEO for Microarray Profiles   CH466582 (Get FASTA) Search GEO for Microarray Profiles   M35186 (Get FASTA) Search GEO for Microarray Profiles   X15191 (Get FASTA) Search GEO for Microarray Profiles Reference Sequences RefSeq Acc Id: NM_009693 RefSeq Status: REVIEWED Type: CODING Protein Acc Id: NP_033823 Peptide Label: precursor Position: Map Chr Position Strand Source Mouse Genome Assembly GRCm38 12 7,977,677 - 8,016,839 + ENTREZGENE Mouse cM Map 12   + ENTREZGENE Mouse Celera Assembly 12 8,374,429 - 8,411,685 + RGD Mouse Genome Assembly Build 37 12 7,984,483 - 8,023,645 + RGD Protein Sequences Protein RefSeqs NP_033823 (Get FASTA) GenBank Protein AAA37246 (Get FASTA)   AAH38263 (Get FASTA)   AAI00608 (Get FASTA)   AAI41358 (Get FASTA)   AAI41361 (Get FASTA)   BAE27983 (Get FASTA)   CAA33265 (Get FASTA)   E9Q414 (Get FASTA)   EDK98393 (Get FASTA) Promoters RGD ID: 6822727 Promoter ID: MM_KWN:11119 Type: Non-CpG SO ACC ID: SO:0000170 Source: MPROMDB Tissues & Cell Lines: Liver Transcripts: UC007MZF.1 Position: Map Chr Position Strand Source Mouse Genome Assembly Build 36.1 12 8,016,766 - 8,019,617 + MPROMDB Additional Information External Database Links Database Acc Id Source(s) Ensembl Genes ENSMUSG00000020609 ENTREZGENE Ensembl Protein ENSMUSP00000036044 ENTREZGENE Ensembl Transcript ENSMUST00000037811 ENTREZGENE Entrez Gene 238055 ENTREZGENE Gene3D-CATH Vitellinogen_b-sht_N UniProtKB/Swiss-Prot   Vitellinogen_open_b-sht_sub1 UniProtKB/Swiss-Prot   Vitellinogen_open_b-sht_sub2 UniProtKB/Swiss-Prot HomoloGene Group ID 328 ENTREZGENE InterPro ApoB100_C UniProtKB/Swiss-Prot   Lipid_transp_b-sht_shell UniProtKB/Swiss-Prot   Lipid_transpt_N UniProtKB/Swiss-Prot   Lipid_transpt_open_b-sht UniProtKB/Swiss-Prot   Vitellinogen_b-sht_N UniProtKB/Swiss-Prot   Vitellinogen_open_b-sht UniProtKB/Swiss-Prot   Vitellinogen_open_b-sht_sub1 UniProtKB/Swiss-Prot   Vitellinogen_open_b-sht_sub2 UniProtKB/Swiss-Prot   Vitellinogen_superhlx UniProtKB/Swiss-Prot IPI IPI00666034 UniProtKB/Swiss-Prot   IPI00974706 UniProtKB/TrEMBL   IPI00986319 UniProtKB/TrEMBL   IPI00990270 UniProtKB/TrEMBL KEGG Report mmu:238055 ENTREZGENE, UniProtKB/Swiss-Prot MGD MGI:88052 ENTREZGENE Pfam ApoB100_C UniProtKB/Swiss-Prot   DUF1081 UniProtKB/Swiss-Prot   DUF1943 UniProtKB/Swiss-Prot   Vitellogenin_N UniProtKB/Swiss-Prot PharmGKB APOB RGD PROSITE VITELLOGENIN UniProtKB/Swiss-Prot SMART LPD_N UniProtKB/Swiss-Prot Superfamily-SCOP Lipid_transp_b-sht_shell UniProtKB/Swiss-Prot   LV_superhelical UniProtKB/Swiss-Prot UniGene Mm.221239 ENTREZGENE UniProt APOB_MOUSE UniProtKB/Swiss-Prot   E9Q1Y3_MOUSE UniProtKB/TrEMBL   E9Q4G4_MOUSE UniProtKB/TrEMBL   F7A3M3_MOUSE UniProtKB/TrEMBL Nomenclature History Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status 2011-08-17 Apob  apolipoprotein B  Apob  apolipoprotein B  Symbol and/or name change 39860 APPROVED

More on Apob Entrez Gene Ensembl Gene Genome Browser MGI Report NCBI Map Viewer Vista Vista + UCSC RGD Object Information RGD ID: 735788 Created: 2004-02-06 Species: Mus musculus Last Modified: 2013-04-02 Status: ACTIVE